Willy Noort

Willy Noort

Auto-generated profile, based on publicly available information

Willy Noort

Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Science Advances
Verified
Journal Article
Open access
DPDorien Pastoors
Dorien Pastoors
MHMarije Havermans
Marije Havermans
RMRoger Mulet-Lazaro
Roger Mulet-Lazaro
DBDuncan Brian
Duncan Brian
WNWilly Noort
Willy Noort
RDRuud Delwel
Ruud Delwel
Acute myeloid leukemia (AML) driven by the activation of EVI1 due to chromosome 3q26/ MECOM rearrangements is incurable. Because transcription factors such as EVI1 are notoriously hard to target, insight into the mechanism by which EVI1 drives myeloid transformation could provide alternative avenues for therapy. Applying protein folding predictions combined with proteomics technologies, we demonstrate that interaction of EVI1 with CTBP1 and CTBP2 via a single PLDLS motif is indispensable for leukemic transformation. A 4× PLDLS repeat construct outcompetes binding of EVI1 to CTBP1 and CTBP2 and inhibits proliferation of 3q26/ MECOM rearranged AML in vitro and in xenotransplant models. This proof-of-concept study opens the possibility to target one of the most incurable forms of AML with specific EVI1-CTBP inhibitors. This has important implications for other tumor types with aberrant expression of EVI1 and for cancers transformed by different CTBP-dependent oncogenic transcription factors.